Universe Pharmaceuticals INC (UPC)
NASDAQ: UPC · IEX Real-Time Price · USD
2.195
+0.295 (15.53%)
Mar 28, 2024, 9:38 AM EDT - Market open

UPC Income Statement

Millions USD. Fiscal year is Oct - Sep.
Year 20232022202120202019
Revenue
32.3140.1447.9830.733.23
Revenue Growth (YoY)
-19.52%-16.34%56.27%-7.60%-
Cost of Revenue
21.9918.2522.6616.6119.82
Gross Profit
10.3221.8925.3314.0913.41
Selling, General & Admin
8.9821.696.273.263.04
Research & Development
4.867.645.470.580.62
Operating Expenses
13.8429.3311.743.843.65
Operating Income
-3.53-7.4413.5910.259.75
Interest Expense / Income
0.160.160.10.120.13
Other Expense / Income
0.170.38-0.190.03-0.03
Pretax Income
-3.85-7.9813.6810.19.65
Income Tax
2.310.752.362.542.1
Net Income
-6.16-8.7411.327.567.55
Net Income Growth
--49.77%0.09%-
Shares Outstanding (Basic)
44333
Shares Outstanding (Diluted)
44333
Shares Change
-14.59%18.63%--
EPS (Basic)
-1.70-2.413.582.822.82
EPS (Diluted)
-1.70-2.413.582.822.82
EPS Growth
--26.95%0%-
Free Cash Flow
1.08-1.41-15.596.0613.12
Free Cash Flow Per Share
0.30-0.39-4.932.274.92
Gross Margin
31.93%54.53%52.78%45.90%40.35%
Operating Margin
-10.92%-18.53%28.32%33.39%29.35%
Profit Margin
-19.08%-21.76%23.59%24.62%22.73%
Free Cash Flow Margin
3.33%-3.50%-32.49%19.75%39.48%
Effective Tax Rate
--17.24%25.17%21.77%
EBITDA
-3.18-7.2914.2310.6310.2
EBITDA Margin
-9.85%-18.15%29.65%34.63%30.70%
Depreciation & Amortization
0.510.530.450.410.42
EBIT
-3.69-7.8213.7810.229.78
EBIT Margin
-11.43%-19.48%28.72%33.30%29.44%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).